JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Last updated: 01 November 2019
Lynparza (olaparib) is the first PARP inhibitor approved to treat breast cancer, and the first medicine ever for metastatic breast cancer who have a “BRCA” gene mutation.Read more
